Stomach cancer treatment and diagnostics abroad

Stomach cancer is a malignant disease of the stomach, most often an adenocarcinoma arising in its lining. It is different from common digestive conditions, and symptoms such as indigestion or upper abdominal discomfort do not establish the diagnosis. Confirmation usually involves endoscopy and examination of tissue. Treatment depends on the precise tumour type, location, extent, relevant biomarkers and the person's overall health. Other tumours arising in the stomach, such as lymphoma or gastrointestinal stromal tumour, need different pathways.

For a specialist consultation abroad, prepare the endoscopy and pathology reports, original scan files and details of previous treatment. Ask which findings still need review, whether additional staging or biomarker tests would change care, and what the proposed treatment aims to achieve. Discuss nutrition, recovery and continuing treatment at home, together with the written estimate. A care plan should be agreed for your diagnosis rather than selected from a standard package.

Symptoms and the exact tumour type

Persistent indigestion, feeling full unusually quickly, loss of appetite, unexplained weight loss or difficulty swallowing warrant medical assessment. These symptoms can have other causes and do not prove cancer. New, worsening or persistent symptoms should be checked rather than attributed automatically to gastritis or reflux.

Most stomach cancers are adenocarcinomas. Lymphoma, gastrointestinal stromal tumour and other less common tumours can also arise there, but their treatment differs. The pathology report should identify the diagnosis before recommendations are compared.

Diagnosis, staging and biomarkers

Gastroenterology assessment commonly includes upper endoscopy with biopsy to examine suspicious tissue. If cancer is confirmed, scans and, in selected cases, endoscopic ultrasound or laparoscopy help assess its extent. Not everyone needs every investigation. The team combines results to decide whether an operation is appropriate and whether treatment should start with medicines.

Biomarker testing can influence systemic treatment, particularly in advanced disease. Relevant findings may include HER2, PD-L1, mismatch repair or microsatellite instability, and CLDN18.2. Which tests are needed depends on the clinical setting and available treatments; a positive result does not guarantee benefit.

Choosing treatment

Some carefully selected early cancers can be removed endoscopically. Other potentially removable cancers may require surgery involving part or all of the stomach and nearby lymph nodes, sometimes with chemotherapy before or after surgery. The approach depends on the stage and health of the patient. Advanced disease may be managed with chemotherapy, targeted medicines, immunotherapy or symptom-directed treatment. Radiotherapy has a role in selected situations rather than being required for everyone.

Preparing for care and nutritional follow-up

When comparing oncology services, ask who will review pathology, staging and nutrition together. Confirm whether tissue slides, blocks or translated reports are needed. Request the treatment goals, alternatives, cost inclusions and expected care arrangements in writing. After stomach surgery, eating patterns and nutrient absorption can change; dietetic support and monitoring may be needed. Agree who will manage follow-up and any ongoing treatment after returning home.

Frequently asked questions

Does indigestion mean stomach cancer?

No. Indigestion has many causes, but persistent or changing symptoms need assessment.

Must the whole stomach be removed?

No. The tumour's location and extent determine whether endoscopic treatment, partial surgery or another approach is appropriate.

Are the same medicines suitable for everyone?

No. Biomarkers, disease extent, previous therapy and health affect the choice.

Is follow-up only about checking for recurrence?

No. It can also address nutrition, weight, treatment effects and practical support.